These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16629780)

  • 41. [Cost-effectiveness of salmeterol/fluticasone combination therapy vs. fluticasone propionate in Japanese asthmatic patients].
    Tohda Y; Nishima S; Arakawa I; Shiragami M; Miyamoto T
    Yakugaku Zasshi; 2010 Apr; 130(4):593-603. PubMed ID: 20372007
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Budget impact analysis of a fixed-dose combination of fluticasone propionate and formoterol fumarate (FP/FORM) in a pressurized metered-dose inhaler (pMDI) for asthma.
    Dunlop W; Heron L; Fox G; Greaney M
    Adv Ther; 2013 Oct; 30(10):933-44. PubMed ID: 24194361
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone.
    Katial RK; Bernstein D; Prazma CM; Lincourt WR; Stempel DA
    Allergy Asthma Proc; 2011; 32(2):127-36. PubMed ID: 21189151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
    Delea TE; Hagiwara M; Stanford RH; Stempel DA
    Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
    Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
    Friedman HS; Eid NS; Crespi S; Wilcox TK; Reardon G
    Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma.
    O'Connor RD; O'Donnell JC; Pinto LA; Wiener DJ; Legorreta AP
    Chest; 2002 Apr; 121(4):1028-35. PubMed ID: 11948029
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and tolerability of salmeterol/fluticasone propionate versus fluticasone propionate in asthma patients: a randomized, double-blind study.
    Lee YS; Lin HC; Huang CD; Lee KY; Liu CY; Yu CT; Wang CH; Kuo HP
    Chang Gung Med J; 2011; 34(4):382-94. PubMed ID: 21880193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children.
    de Blic J; Ogorodova L; Klink R; Sidorenko I; Valiulis A; Hofman J; Bennedbaek O; Anderton S; Attali V; Desfougeres JL; Poterre M
    Pediatr Allergy Immunol; 2009 Dec; 20(8):763-71. PubMed ID: 19239660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adding salmeterol to fluticasone propionate or increasing the dose of fluticasone propionate in patients with asthma.
    Delea TE; Hagiwara M; Stempel DA; Stanford RH
    Allergy Asthma Proc; 2010; 31(3):211-8. PubMed ID: 20615321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.
    Peters DH; Faulds D
    Pharmacoeconomics; 1995 Jun; 7(6):562-74. PubMed ID: 10155341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves.
    Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
    Ann Allergy Asthma Immunol; 2005 Aug; 95(2):181-9. PubMed ID: 16136769
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Salmeterol and fluticasone in young children with multiple-trigger wheeze.
    Mäkelä MJ; Malmberg LP; Csonka P; Klemola T; Kajosaari M; Pelkonen AS
    Ann Allergy Asthma Immunol; 2012 Jul; 109(1):65-70. PubMed ID: 22727160
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma.
    Aalbers R; Backer V; Kava TT; Omenaas ER; Sandström T; Jorup C; Welte T
    Curr Med Res Opin; 2004; 20(2):225-40. PubMed ID: 15006018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma.
    Ericsson K; Bantje TA; Huber RM; Borg S; Bateman ED
    Respir Med; 2006 Apr; 100(4):586-94. PubMed ID: 16274980
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients.
    Adachi M; Aizawa H; Ishihara K; Ohta K; Sano Y; Taniguchi H; Nakashima M
    Respir Med; 2008 Jul; 102(7):1055-64. PubMed ID: 18394875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of prevalence, cost, and outcomes of a combination of salmeterol and fluticasone therapy to common asthma treatments.
    Wang SW; Liu X; Wiener DJ; Sennett C; Bowers BW; Legorreta AP
    Am J Manag Care; 2001 Sep; 7(9):913-22. PubMed ID: 11570024
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.
    Najafzadeh M; Marra CA; Sadatsafavi M; Aaron SD; Sullivan SD; Vandemheen KL; Jones PW; Fitzgerald JM
    Thorax; 2008 Nov; 63(11):962-7. PubMed ID: 18621985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.